Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study

Viruses. 2022 Dec 25;15(1):65. doi: 10.3390/v15010065.

Abstract

As the Corona Disease 2019 (COVID-19) caused by SARS-CoV-2 persists, vaccination is one of the key measures to contain the spread. Side effects (SE) from vaccination are one of the reasons for reluctance to vaccinate. We systematically investigated self-reported SE after the first, second, and booster vaccinations. The data were collected during the TüSeRe: exact study (Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung). Employees of health and research institutions were invited to participate. Study participants were asked to fill out an online questionnaire and report their SE after each dose of SARS-CoV-2 vaccination. A total of 1046 participants (mean age: 44 ± 12.9 years; female, n = 815 (78%); male, n = 231 (22%)) were included in the analysis. Local and systemic SE were more frequent after receiving the vector-based vaccine ChAdOx1 nCoV-19 in the first vaccination. However, local and systemic SE were more common after receiving mRNA vaccines (BNT162b2, mRNA-1273) in the second vaccination. Compared to the BNT162b2 vaccine, more SE have been observed after receiving the mRNA-1273 vaccine in the booster vaccination. In multivariate analysis, local and systemic side effects were associated with vaccine type, age and gender. Local and systemic SE are common after SARS-CoV-2 vaccines. The frequency of self-reported local and systemic SE differ significantly between mRNA and vector-based vaccines.

Keywords: COVID-19; adverse event; reactogenicity; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Adult
  • BNT162 Vaccine
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19
  • Drug-Related Side Effects and Adverse Reactions*
  • Female
  • Health Personnel
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Vaccination / adverse effects
  • Vaccines*

Substances

  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine
  • ChAdOx1 nCoV-19
  • COVID-19 Vaccines
  • Vaccines

Associated data

  • DRKS/DRKS00029013

Grants and funding

This work was supported by grants from the German Research Foundation and from the Herzstiftung to T.B. (BA5158/4 and TSG-Study), by special funds from the state of Baden-Württemberg for coagulation research and Blood donation service of the German Red Cross to TB, and by the State Ministry of Baden-Württemberg for Economic Affairs, Labor and Tourism (grant numbers FKZ 3-4332.62-NMI-67, FKZ 3-4332.62-NMI-68).